These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 6119637)

  • 1. Pharmacological properties of new antipsychotic agents: use of animal models.
    Puech AJ; Rioux P; Poncelet M; Brochet D; Chermat R; Simon P
    Neuropharmacology; 1981 Dec; 20(12B):1279-84. PubMed ID: 6119637
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacological studies on timiperone, a new neuroleptic drug. Part I: Behavior effects.
    Yamasaki T; Kojima H; Sakurai T; Kasahara A; Watanabe S; Fujiwara M; Ueki S
    Arzneimittelforschung; 1981; 31(4):701-7. PubMed ID: 6113833
    [No Abstract]   [Full Text] [Related]  

  • 3. A critical assessment of behavioural test procedures used to analyse dopaminergic and antidopaminergic drugs.
    Nohria V
    Methods Find Exp Clin Pharmacol; 1983; 5(6):357-64. PubMed ID: 6137599
    [No Abstract]   [Full Text] [Related]  

  • 4. Classification of neuroleptics--zotepine.
    Puech AJ; Martin P
    Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):1-3. PubMed ID: 2883676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological activity of picobenzide (3,5-dimethyl-N-(pyridin-4-ylmethyl)benzamide) analogues as potential antipsychotic agents.
    Gradillas A; López B; Braña MF; Sancho I; Pérez-García C; Alguacil LF
    Arzneimittelforschung; 2005; 55(12):725-9. PubMed ID: 16430025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparative study of the pharmacological activity of N-(4-picolyl)-3,5-dimethylbenzamide (M-14012-4) and its N-oxide metabolite (M-3312-4). New pharmacological aspects].
    Casais L; Colom A; Martín del Río MP; Vallejo M; Cuenca E
    Arch Farmacol Toxicol; 1979 Dec; 5(3):159-64. PubMed ID: 44673
    [No Abstract]   [Full Text] [Related]  

  • 7. Synthesis and pharmacological investigations of new 6-oxo-1,2,3,4-tetrahydro-6H-pyrimido[2,1-b]quinazoline derivatives.
    Korzycka L; Szadowska A; Pakulska W
    Pharmazie; 1994 Nov; 49(11):815-9. PubMed ID: 7838867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic aspects of some behavioral effects of psychotropic drugs.
    Melzacka M
    Pol J Pharmacol Pharm; 1984; 36(2-3):117-36. PubMed ID: 6147827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological evaluation of clomacran, a new potent psychotropic agent.
    Fowler PJ; Zirkle CL; Macko E; Kaiser C; Sarau H; Tedeschi DH
    Arzneimittelforschung; 1977; 27(4):866-72. PubMed ID: 17419
    [No Abstract]   [Full Text] [Related]  

  • 10. Differential actions of typical and atypical neuroleptic agents on two behavioural effects of apomorphine in the mouse [proceedings].
    Costall B; Naylor RJ; Nohria V
    Br J Pharmacol; 1978 Jun; 63(2):381P-382P. PubMed ID: 27276
    [No Abstract]   [Full Text] [Related]  

  • 11. 7-[3-(1-piperidinyl)propoxy]chromenones as potential atypical antipsychotics.
    Bolós J; Gubert S; Anglada L; Planas JM; Burgarolas C; Castelló JM; Sacristán A; Ortiz JA
    J Med Chem; 1996 Jul; 39(15):2962-70. PubMed ID: 8709130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neuroleptic-like activity of the tripeptide neurotensin analog GZR-123].
    Guzevatykh LS; Ostrovskaia RU; Gudasheva TA; Zaĭtseva NI; Voronina TA
    Eksp Klin Farmakol; 2002; 65(1):3-6. PubMed ID: 12025780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-activity relationships of a series of novel (piperazinylbutyl)thiazolidinone antipsychotic agents related to 3-[4-[4-(6-fluorobenzo[b]thien-3-yl)-1-piperazinyl]butyl]-2,5,5- trimethyl-4-thiazolidinone maleate.
    Hrib NJ; Jurcak JG; Bregna DE; Burgher KL; Hartman HB; Kafka S; Kerman LL; Kongsamut S; Roehr JE; Szewczak MR; Woods-Kettelberger AT; Corbett R
    J Med Chem; 1996 Sep; 39(20):4044-57. PubMed ID: 8831770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral pharmacologic studies in the monkey with DD-3480.
    Shibuya T; Nishimori T; Matsuda H; Chen PC
    Int J Clin Pharmacol Ther Toxicol; 1982 Jun; 20(6):251-4. PubMed ID: 6125481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central nervous system activity of the proanthocyanidin-rich fraction obtained from Croton celtidifolius in rats.
    Moreira EL; Rial D; Duarte FS; de Carvalho CR; Horst H; Pizzolatti MG; Prediger RD; Ribeiro-do-Valle RM
    J Pharm Pharmacol; 2010 Aug; 62(8):1061-8. PubMed ID: 20663041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behavioural data suggesting the plurality of central dopamine receptors.
    Costentin J; Dubuc I; Protais P
    Adv Biochem Psychopharmacol; 1983; 37():289-97. PubMed ID: 6138951
    [No Abstract]   [Full Text] [Related]  

  • 17. Neuroleptic versus antidepressant activity of sulpiride isomers in the rat.
    Montanaro N; Dall'Olio R; Gandolfi O; Vaccheri A
    Adv Biochem Psychopharmacol; 1982; 31():341-6. PubMed ID: 6123224
    [No Abstract]   [Full Text] [Related]  

  • 18. Induction of two distinct behavioural responses by chronic treatment with ampomorphine.
    Kenny M; Lynch M; Leonard BE
    J Neurosci Res; 1980; 5(1):35-42. PubMed ID: 7189789
    [No Abstract]   [Full Text] [Related]  

  • 19. Injection of apomorphine--a test to predict individual different dopaminergic sensitivity?
    Surmann A; Havemann-Reinecke U
    J Neural Transm Suppl; 1995; 45():143-55. PubMed ID: 8748620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroleptic/dopamine receptors: elevation and reversal.
    List S; Seeman P
    Adv Biochem Psychopharmacol; 1980; 24():95-101. PubMed ID: 6105811
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.